Enrollment and initial dosing of PAS-004 at 30 milligrams has begun in three patients with MAPK pathway-driven advanced solid ...

Pancreatic cancer is a leading cause of cancer-related death, with a five-year survival rate of 13%. The high mortality is ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

In a recent paper, published in Nature, researchers from the University of Michigan have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and ...

Terms of Service and Privacy Policy. After two long years, the highly anticipated second season of HBO’s The Last of Us is almost here. In the new season, five ...

These pathways include nuclear factor- B, p38 mitogen-activated protein kinase, NH 2-terminal Jun kinases/stress-activated protein kinases, hexosamines, and others. In addition, there is evidence ...